Which has better earnings and valuation, TECH or RGEN?

Bio-Techne has higher revenue and earnings than Repligen. Bio-Techne is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Techne $1.22B 9.35 $181.86M $1.15 63.03 Repligen $738.26M 13.41 $48.89M $0.73 240.30

Is TECH or RGEN more profitable?

Bio-Techne has a net margin of 14.97% compared to Repligen's net margin of 5.29%. Bio-Techne's return on equity of 13.23% beat Repligen's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Techne 14.97% 13.23% 10.61% Repligen 5.29% 5.30% 3.79%

Does the media favor TECH or RGEN?

In the previous week, Repligen had 1 more articles in the media than Bio-Techne. MarketBeat recorded 5 mentions for Repligen and 4 mentions for Bio-Techne. Repligen's average media sentiment score of 1.09 beat Bio-Techne's score of 0.53 indicating that Repligen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor A or RGEN?

In the previous week, Agilent Technologies had 6 more articles in the media than Repligen. MarketBeat recorded 11 mentions for Agilent Technologies and 5 mentions for Repligen. Repligen's average media sentiment score of 1.09 beat Agilent Technologies' score of 0.92 indicating that Repligen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agilent Technologies 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, BIO or RGEN?

Bio-Rad Laboratories has higher revenue and earnings than Repligen. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Rad Laboratories $2.58B 3.77 $759.90M $8.25 44.17 Repligen $738.26M 13.41 $48.89M $0.73 240.30

Does the media prefer BIO or RGEN?

In the previous week, Repligen had 4 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 5 mentions for Repligen and 1 mentions for Bio-Rad Laboratories. Repligen's average media sentiment score of 1.09 beat Bio-Rad Laboratories' score of 0.00 indicating that Repligen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Rad Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Repligen 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, RGEN or DHR?

Danaher has higher revenue and earnings than Repligen. Danaher is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Repligen $738.26M 13.41 $48.89M $0.73 240.30 Danaher $24.57B 6.39 $3.61B $5.63 39.66

Is RGEN or DHR more profitable?

Danaher has a net margin of 15.95% compared to Repligen's net margin of 5.29%. Danaher's return on equity of 11.04% beat Repligen's return on equity. Company Net Margins Return on Equity Return on Assets Repligen 5.29% 5.30% 3.79% Danaher 15.95% 11.04% 6.81%

Does the media refer more to RGEN or DHR?

In the previous week, Danaher had 65 more articles in the media than Repligen. MarketBeat recorded 70 mentions for Danaher and 5 mentions for Repligen. Danaher's average media sentiment score of 1.41 beat Repligen's score of 1.09 indicating that Danaher is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Danaher 55 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RGEN or MTD?

In the previous week, Mettler-Toledo International had 7 more articles in the media than Repligen. MarketBeat recorded 12 mentions for Mettler-Toledo International and 5 mentions for Repligen. Repligen's average media sentiment score of 1.09 beat Mettler-Toledo International's score of 0.53 indicating that Repligen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mettler-Toledo International 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Repligen (RGEN) Competitors

$178.20 +2.78 (+1.58%)

Closing price 04:00 PM Eastern

Extended Trading

$178.23 +0.03 (+0.02%)

As of 05:52 PM Eastern

Compare

RGEN vs. TECH, A, BIO, DHR, and MTD

Should you buy Repligen stock or one of its competitors? Repligen's main competitors and comparable companies include Bio-Techne (TECH), Agilent Technologies (A), Bio-Rad Laboratories (BIO), Danaher (DHR), and Mettler-Toledo International (MTD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Repligen compare to Bio-Techne?

Bio-Techne (NASDAQ:TECH) and Repligen (NASDAQ:RGEN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

99.0% of Bio-Techne shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 1.3% of Bio-Techne shares are held by company insiders. Comparatively, 0.6% of Repligen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Bio-Techne has higher revenue and earnings than Repligen. Bio-Techne is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.35	$181.86M	$1.15	63.03
Repligen	$738.26M	13.41	$48.89M	$0.73	240.30

Bio-Techne has a net margin of 14.97% compared to Repligen's net margin of 5.29%. Bio-Techne's return on equity of 13.23% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	14.97%	13.23%	10.61%
Repligen	5.29%	5.30%	3.79%

Bio-Techne has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market. Comparatively, Repligen has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

In the previous week, Repligen had 1 more articles in the media than Bio-Techne. MarketBeat recorded 5 mentions for Repligen and 4 mentions for Bio-Techne. Repligen's average media sentiment score of 1.09 beat Bio-Techne's score of 0.53 indicating that Repligen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bio-Techne presently has a consensus target price of $68.92, suggesting a potential downside of 4.91%. Repligen has a consensus target price of $173.21, suggesting a potential downside of 1.26%. Given Repligen's stronger consensus rating and higher possible upside, analysts clearly believe Repligen is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	0 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.12
Repligen	0 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.89

Summary

Bio-Techne beats Repligen on 9 of the 17 factors compared between the two stocks.

How does Repligen compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and Repligen (NASDAQ:RGEN) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

In the previous week, Agilent Technologies had 6 more articles in the media than Repligen. MarketBeat recorded 11 mentions for Agilent Technologies and 5 mentions for Repligen. Repligen's average media sentiment score of 1.09 beat Agilent Technologies' score of 0.92 indicating that Repligen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilent Technologies	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agilent Technologies has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market. Comparatively, Repligen has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

Agilent Technologies presently has a consensus target price of $173.65, indicating a potential upside of 1.16%. Repligen has a consensus target price of $173.21, indicating a potential downside of 1.26%. Given Agilent Technologies' higher possible upside, equities research analysts clearly believe Agilent Technologies is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilent Technologies	0 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.79
Repligen	0 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.89

Agilent Technologies has higher revenue and earnings than Repligen. Agilent Technologies is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilent Technologies	$6.95B	6.97	$1.30B	$5.08	33.79
Repligen	$738.26M	13.41	$48.89M	$0.73	240.30

Agilent Technologies has a net margin of 19.53% compared to Repligen's net margin of 5.29%. Agilent Technologies' return on equity of 24.45% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilent Technologies	19.53%	24.45%	13.09%
Repligen	5.29%	5.30%	3.79%

97.6% of Repligen shares are held by institutional investors. 0.6% of Repligen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Agilent Technologies beats Repligen on 10 of the 17 factors compared between the two stocks.

How does Repligen compare to Bio-Rad Laboratories?

Bio-Rad Laboratories (NYSE:BIO) and Repligen (NASDAQ:RGEN) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Bio-Rad Laboratories has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, Repligen has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

Bio-Rad Laboratories presently has a consensus target price of $343.33, suggesting a potential downside of 5.77%. Repligen has a consensus target price of $173.21, suggesting a potential downside of 1.26%. Given Repligen's stronger consensus rating and higher possible upside, analysts clearly believe Repligen is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20
Repligen	0 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.89

Bio-Rad Laboratories has a net margin of 8.59% compared to Repligen's net margin of 5.29%. Repligen's return on equity of 5.30% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	8.59%	3.54%	2.48%
Repligen	5.29%	5.30%	3.79%

65.2% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 30.3% of Bio-Rad Laboratories shares are owned by company insiders. Comparatively, 0.6% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Bio-Rad Laboratories has higher revenue and earnings than Repligen. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58B	3.77	$759.90M	$8.25	44.17
Repligen	$738.26M	13.41	$48.89M	$0.73	240.30

In the previous week, Repligen had 4 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 5 mentions for Repligen and 1 mentions for Bio-Rad Laboratories. Repligen's average media sentiment score of 1.09 beat Bio-Rad Laboratories' score of 0.00 indicating that Repligen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Rad Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Repligen	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Repligen beats Bio-Rad Laboratories on 12 of the 17 factors compared between the two stocks.

How does Repligen compare to Danaher?

Repligen (NASDAQ:RGEN) and Danaher (NYSE:DHR) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Danaher has a net margin of 15.95% compared to Repligen's net margin of 5.29%. Danaher's return on equity of 11.04% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	5.29%	5.30%	3.79%
Danaher	15.95%	11.04%	6.81%

Repligen currently has a consensus target price of $173.21, indicating a potential downside of 1.26%. Danaher has a consensus target price of $235.41, indicating a potential upside of 5.42%. Given Danaher's stronger consensus rating and higher possible upside, analysts plainly believe Danaher is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	0 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.89
Danaher	0 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91

Repligen has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, Danaher has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

In the previous week, Danaher had 65 more articles in the media than Repligen. MarketBeat recorded 70 mentions for Danaher and 5 mentions for Repligen. Danaher's average media sentiment score of 1.41 beat Repligen's score of 1.09 indicating that Danaher is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Danaher	55 Very Positive mention(s)	3 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.6% of Repligen shares are held by institutional investors. Comparatively, 79.1% of Danaher shares are held by institutional investors. 0.6% of Repligen shares are held by insiders. Comparatively, 10.8% of Danaher shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Danaher has higher revenue and earnings than Repligen. Danaher is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$738.26M	13.41	$48.89M	$0.73	240.30
Danaher	$24.57B	6.39	$3.61B	$5.63	39.66

Summary

Danaher beats Repligen on 12 of the 16 factors compared between the two stocks.

How does Repligen compare to Mettler-Toledo International?

Repligen (NASDAQ:RGEN) and Mettler-Toledo International (NYSE:MTD) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Mettler-Toledo International has a net margin of 21.91% compared to Repligen's net margin of 5.29%. Repligen's return on equity of 5.30% beat Mettler-Toledo International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	5.29%	5.30%	3.79%
Mettler-Toledo International	21.91%	-1,212.14%	25.11%

Mettler-Toledo International has higher revenue and earnings than Repligen. Mettler-Toledo International is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$738.26M	13.41	$48.89M	$0.73	240.30
Mettler-Toledo International	$4.03B	7.95	$869.19M	$44.43	35.96

Repligen has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, Mettler-Toledo International has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market.

In the previous week, Mettler-Toledo International had 7 more articles in the media than Repligen. MarketBeat recorded 12 mentions for Mettler-Toledo International and 5 mentions for Repligen. Repligen's average media sentiment score of 1.09 beat Mettler-Toledo International's score of 0.53 indicating that Repligen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mettler-Toledo International	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.6% of Repligen shares are held by institutional investors. Comparatively, 95.1% of Mettler-Toledo International shares are held by institutional investors. 0.6% of Repligen shares are held by company insiders. Comparatively, 0.7% of Mettler-Toledo International shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Repligen currently has a consensus target price of $173.21, indicating a potential downside of 1.26%. Mettler-Toledo International has a consensus target price of $1,469.15, indicating a potential downside of 8.04%. Given Repligen's stronger consensus rating and higher probable upside, analysts plainly believe Repligen is more favorable than Mettler-Toledo International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	0 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.89
Mettler-Toledo International	1 Sell rating(s)	9 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.27

Summary

Repligen beats Mettler-Toledo International on 9 of the 17 factors compared between the two stocks.

Get Repligen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RGEN vs. The Competition

Export

Metric	Repligen	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.06B	$10.68B	$7.28B	$12.93B
Dividend Yield	N/A	1.45%	2.51%	22.89%
P/E Ratio	244.11	31.87	275.31	25.30
Price / Sales	13.62	103.31	557.34	76.35
Price / Cash	50.49	27.42	77.16	53.04
Price / Book	4.76	6.08	10.51	5.92
Net Income	$48.89M	$56.67B	$3.50B	$381.04M
7 Day Performance	6.57%	-3.26%	-4.32%	-4.38%
1 Month Performance	6.07%	4.53%	-8.64%	-7.25%
1 Year Performance	20.08%	24.62%	2.05%	-4.95%

Repligen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RGEN Repligen	2.2086 of 5 stars	$178.20 +1.6%	$173.21 -2.8%	+18.0%	$10.06B	$738.26M	244.11	2,000	Positive News
TECH Bio-Techne	2.6647 of 5 stars	$72.58 +0.2%	$68.92 -5.0%	+21.5%	$11.35B	$1.22B	63.11	3,000
A Agilent Technologies	3.6601 of 5 stars	$171.17 +2.0%	$170.33 -0.5%	+24.0%	$48.29B	$7.37B	33.69	18,100	Trending News Analyst Forecast
BIO Bio-Rad Laboratories	0.6254 of 5 stars	$380.39 +3.0%	$343.33 -9.7%	+20.0%	$9.87B	$2.58B	46.11	7,450
DHR Danaher	3.4749 of 5 stars	$220.88 +3.2%	$234.09 +6.0%	+8.7%	$150.48B	$25.11B	39.23	60,000	Trending News Upcoming Earnings Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RGEN) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Repligen (RGEN) Competitors

RGEN vs. TECH, A, BIO, DHR, and MTD

How does Repligen compare to Bio-Techne?

Summary

How does Repligen compare to Agilent Technologies?

Summary

How does Repligen compare to Bio-Rad Laboratories?

Summary

How does Repligen compare to Danaher?

Summary

How does Repligen compare to Mettler-Toledo International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGEN vs. The Competition

Repligen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Repligen (RGEN) Competitors

RGEN vs. TECH, A, BIO, DHR, and MTD

How does Repligen compare to Bio-Techne?

Do insiders and institutionals hold more shares of TECH or RGEN?

Which has better earnings and valuation, TECH or RGEN?

Is TECH or RGEN more profitable?

Which has more risk & volatility, TECH or RGEN?

Does the media favor TECH or RGEN?

Do analysts prefer TECH or RGEN?

Summary

How does Repligen compare to Agilent Technologies?

Does the media favor A or RGEN?

Which has more risk & volatility, A or RGEN?

Do analysts recommend A or RGEN?

Which has higher valuation and earnings, A or RGEN?

Is A or RGEN more profitable?

Do insiders & institutionals believe in A or RGEN?

Summary

How does Repligen compare to Bio-Rad Laboratories?

Which has more volatility & risk, BIO or RGEN?

Do analysts rate BIO or RGEN?

Is BIO or RGEN more profitable?

Do insiders & institutionals hold more shares of BIO or RGEN?

Which has stronger valuation & earnings, BIO or RGEN?

Does the media prefer BIO or RGEN?

Summary

How does Repligen compare to Danaher?

Is RGEN or DHR more profitable?

Do analysts rate RGEN or DHR?

Which has more risk & volatility, RGEN or DHR?

Does the media refer more to RGEN or DHR?

Do institutionals & insiders hold more shares of RGEN or DHR?

Which has stronger earnings & valuation, RGEN or DHR?

Summary

How does Repligen compare to Mettler-Toledo International?

Is RGEN or MTD more profitable?

Which has higher valuation and earnings, RGEN or MTD?

Which has more volatility and risk, RGEN or MTD?

Does the media prefer RGEN or MTD?

Do insiders and institutionals hold more shares of RGEN or MTD?

Do analysts recommend RGEN or MTD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGEN vs. The Competition

Repligen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools